perspective are c5,325 (±9588), c18,045c (±34487) and c41,716 (±35211) at mild, moderate and severe stages respectively in France; c3,125 (±4319), c8,457 (±18374) and c5,069 (±11747) in Italy. Associated EQ-5D utilities are respectively 0.79 (±0.18), 0.39 (±0.37), −0.11 (±0.3) in France; 0.59 (±0.44), 0.39 (±0.42), 0.25 (±0.44) in Italy. The primary cost driver is productivity loss. In France, hospitalization and nursing home costs are the main components of direct costs. For more severely affected patients, medical resource utilization diminishes while caregiver involvement increases significantly (the shift is greater in Italy than France). Physical, mental and social HRQoL domains are all seriously affected. CONCLUSIONS: Euro-HDB is the fi rst study to comprehensively assess the cost and HRQOL burden of HD. The 1:5 cost ratio (Italy : France) is consistent across most of the cost items, suggesting that differences in health care systems, access to health care and cultural attitudes towards caring for patients at home have a large impact on a country's overall costs. Results suggest that HD has greater impact on HRQOL than Parkinson's disease and Alzheimer's disease. The economic burden of Multiple Sclerosis (MS) on society and the individuals concerned is not known. Documenting such costs is essential for several reasons: costs of illness is a key factor of optimal disease management policies, knowledge of cost is useful for allocating research and development. The aim of our study as the fi rst pharmacoeconomic investigation in Iran was to estimate the costs of multiple sclerosis according to severity of disease. Total, direct and indirect costs were compared in 160 patients divided into three groups categorized by disease severity: stage I Expanded Disability Status Scale (EDSS < 2.5), stage II (EDSS 3-4.5) and stage III (EDSS > 5). The majority of these patients (94%) developed relapsing-remitting MS. a minority of the patients (0.2-4%) developed secondary progressive and primary progressive MS. Cost evaluation was performed from the societal perspective and covered the one-year period. The study was carried out at the Division of Neurology at Ghaem Hospital and MS association in Mashhad in northeast of Iran and was approved by the local ethics committee. The mean total cost/patient for one year was estimated at $27,095, $27,997and $31,662 for stage I, II and III, respectively. Both direct and indirect costs increased with MS progression. For indirect cost the main item was productivity loss. The mean extra medicine (treatments for MS symptoms and adverse effects of medications) cost/patient for one year was calculated at $19,036. This study confi rms that MS represents a high economic burden to patients and society, with direct costs greatly exceeding indirect costs. As costs increase with disease progression, treatment efforts should focus on patients in the early stages of MS. Disease support system that monitors a variety of common progressive signs for the MS individuals is a key element of a management program as well.
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University Sains Malaysia, Penang, Malaysia; 2 Mashhad University of Medical Sciences, Mashhad, Khorasan, Iran; 3 UKM, Kuala Lumpur, Malaysia The economic burden of Multiple Sclerosis (MS) on society and the individuals concerned is not known. Documenting such costs is essential for several reasons: costs of illness is a key factor of optimal disease management policies, knowledge of cost is useful for allocating research and development. The aim of our study as the fi rst pharmacoeconomic investigation in Iran was to estimate the costs of multiple sclerosis according to severity of disease. Total, direct and indirect costs were compared in 160 patients divided into three groups categorized by disease severity: stage I Expanded Disability Status Scale (EDSS < 2.5), stage II (EDSS 3-4.5) and stage III (EDSS > 5). The majority of these patients (94%) developed relapsing-remitting MS. a minority of the patients (0.2-4%) developed secondary progressive and primary progressive MS. Cost evaluation was performed from the societal perspective and covered the one-year period. The study was carried out at the Division of Neurology at Ghaem Hospital and MS association in Mashhad in northeast of Iran and was approved by the local ethics committee. The mean total cost/patient for one year was estimated at $27,095, $27,997and $31,662 for stage I, II and III, respectively. Both direct and indirect costs increased with MS progression. For indirect cost the main item was productivity loss. The mean extra medicine (treatments for MS symptoms and adverse effects of medications) cost/patient for one year was calculated at $19,036. This study confi rms that MS represents a high economic burden to patients and society, with direct costs greatly exceeding indirect costs. As costs increase with disease progression, treatment efforts should focus on patients in the early stages of MS. Disease support system that monitors a variety of common progressive signs for the MS individuals is a key element of a management program as well.
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SOCIO-ECONOMIC ASPECTS OF TESTING FOR NEUTRALIZING ANTIBODIES IN MS PATIENTS ON INTERFERON BETA TREATMENT IN AUSTRIA: A COST OF ILLNESS STUDY
Walter E 1 , Brennig C 1 , Schöllbauer V 1 , Mair W 2 , Deisenhammer F 3 1 Institute for Pharmaeconomic Research, Vienna, Austria; 2 Biogen Idec GmbH, Vienna, Austria; 3 University Hospital Innsbruck, Innsbruck, Austria OBJECTIVES: According to EU-guidelines testing all patients on interferon-beta (IFNb) for presence of neutralizing antibodies (NAB) is recommended irrespective of clinical course and stop IFNb or switch to alternatives in patients who developed persistent NAB; based on the fact that development in persistently NAB-positive patients equals that of placebo-treated patients. Economic impact of NAB-testing in MS-patients has not been explored yet. METHODS: This analysis estimated the economic impact of NAB-testing versus not testing during IFNb treatment in MSpatients (n = 3590) on Austria's health care system. a cost of illness model (decision tree combined with an integrated Markov model, time horizon 5 years), based on the cohort of IFNb-treated patients was performed. Two alternatives were compared: Cost-effectiveness of NAB-testing versus no NAB-testing. The NAB-testing arm allowed switching to alternative therapies whereas no-NAB-testing did not. Direct costs comprised all treatment-costs of symptoms due to MS. Indirect costs were not included. All costs represent data from 2010 (discounted at 5%p.a). Clinical data and resource use were determined by literature/experts. Effi cacy assessment was based on the outcome measure "relapses avoided." RESULTS: Total discounted costs for all Austrian MS-patients on IFNb-therapy (incl. testing) from a health care system's perspective amount to c187,764,180 for 5 years. Total costs for all MS-patients without testing amount to c176,331,610. The difference of costs between tested patients, and therefore switching, and not tested patients values c11,432,570. Considering all IFNb-treated patients and a time horizon of 5 years 1400 relapses can be avoided. Testing for NAB leads to costs per relapse avoided of c24,383p.a. versus c27,569p.a. when no tests are done resulting in a difference of c3,186 per patient in favour of NAB-testing. CONCLUSIONS: General NAB-testing in MS-patients on IFNb-therapy is reasonable and cost-effective. Patients switching to effective and more expensive alternatives do not account for higher health care costs. Furthermore, less relapses increase QoL.
PND15 PATIENT CHARACTERISTICS AND CHARGES ASSOCIATED WITH EMERGENCY DEPARTMENT VISITS AMONG PATIENTS WITH A DIAGNOSIS OF RESTLESS LEGS SYNDROME
Meyers J, Candrilli S RTI Health Solutions, Research Triangle Park, NC, USA OBJECTIVES: Restless legs syndrome (RLS) affects 2 to 15% of the US population. Limited data exist on patient characteristics and charges associated with emergency department (ED) visits among patients with RLS. METHODS: Data from the 2007 Healthcare Cost and Utilization Project's Nationwide Emergency Department Sample were used. Patients were selected for inclusion if they had a diagnosis of RLS (ICD-9-CM code 333.94). Study measures included patient demographics and charges associated with the ED visit. Study measures were reported separately for patients with a primary versus secondary RLS diagnosis. Among patients with a secondary RLS diagnosis, the most common primary diagnoses were reported. RESULTS: A total of 6133 patients with a primary RLS diagnosis and 140,931 patients with a secondary RLS diagnosis were identifi ed. Common primary diagnoses among patients with a secondary RLS diagnosis included respiratory symptoms (7.0%), general symptoms (4.6%), and pneumonia (3.7%). Mean (Std. Err.) age was 54.5 (0.6) years among patients with a primary diagnosis and 64.0 (0.3) years among patients with a secondary diagnosis. In both cohorts, over two-thirds of patients were female, the most common geographic regions were the South and Midwest, and Medicare was the most common primary payer (41.0% of patients with a primary diagnosis and 59.3% of patients with a secondary diagnosis). Over 90% of patients with a primary diagnosis had a routine discharge compared to only 26.6% of patients with a secondary diagnosis, and most patients with a secondary diagnosis were admitted to the facility as an inpatient. Mean (Std. Err.) charges were $816 ($48) for patients with a primary diagnosis and $2,043 ($62) for patients with a secondary diagnosis. CONCLUSIONS: This nationally representative study suggests that patients admitted to the ED with RLS accrue substantial costs during their visit. Further research is needed to more fully assess the total economic burden of the disease.
PND16 MODELING THE CLINICAL AND ECONOMIC IMPLICATIONS OF GALANTAMINE IN THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE IN GERMANY
United BioSource Corporation, Lexington, MA, USA; 2 United BioSource CorporationEurope, London, UK; 3 Janssen-Cilag, Neuss, Germany OBJECTIVES: A reimbursement policy issued by the Federal Joint Committee in Germany to reassess the benefi t of cholinesterase inhibitors every six months in order to receive continued coverage by the Statutory Health Insurance triggered an additional need to periodically assess the cost-benefi t of galantamine in the treatment of mild-to-moderate Alzheimer's disease (AD). An economic model specifi cally designed for the purposes of such an assessment was developed using the most up-to-date IQWiG guidelines for cost-benefi t assessment. METHODS: The model uses a discrete event simulation to predict the course of AD through changes in cognition, behavioral disturbance, and function over time, and compare the costs and benefi ts of galantamine versus no-drug treatment and ginkgo biloba. Clinical data were mainly derived from analyses of pooled data from clinical trials. Epidemiological and cost data were obtained from literature and public data sources. Costs (2009 c) from the perspective of the German Statutory Health Insurance were used. Both costs and benefi ts were discounted at 5%. Sensitivity analyses were performed to assess the robustness of the model outcomes. RESULTS: Over a 10-year period, galantamine on average delays time to severe stage of the disease by 3.57 and 3.36 months, compared to no-drug treatment and ginkgo biloba, respectively. Galantamine also reduces time spent institutionalized by 2.34 and 2.21 months, compared to no-drug treatment and ginkgo biloba, respectively. The use of galantamine is projected to yield net savings of c3,978 and c3,972 per patient compared to respective treatments. CONCLUSIONS: Our analyses suggest that compared to no-drug treatment and ginkgo biloba, treatment with galantamine not only improves clinical benefi ts, but also achieves savings in health care costs associated with care for patients with mild-to-moderate AD in Germany.
PND17 MEMANTINE DELAYS THE ADMISSION OF ALZHEIMER'S DISEASE PATIENTS TO NURSING HOME: COST-EFFECTIVENESS ANALYSIS IN FRANCE
Touchon J 1 , Lachaine J 2 , Beauchemin C 2 , Crochard A 3 , Rive B 3 , Bineau S 3 1 Gui de Chauliac Hospital, Montpellier, France; 2 University of Montreal, Montreal, QC, Canada; 3 Lundbeck SAS, Issy-Les-Moulineaux, France OBJECTIVES: To evaluate in the French setting the cost-effectiveness of memantine as adjunct therapy to Cholinesterase inhibitors (ChEI) compared to ChEI monotherapy in Alzheimer's disease (AD) patients. METHODS: A cost-effectiveness analysis employed a 3-state Markov model ("non-institutionalized," "institutionalized" and "dead") and compared the treatment alternatives in terms of time to nursing home admission, Quality Adjusted Life-years (QALYs), and costs over a 7-year time horizon. Annual transition probabilities between states were derived from two observational cohort studies: Lopez et al 2009 (US) for institutionalization probabilities and Helmer et al 2001 (FR) for death probabilities. Costs were valued from health care system and societal perspectives, and included cost of AD medications (French National
